Key TakeawaysThe Medicare Part D and Medicaid pilot program will cover obesity drugs at a $50 copay, but implementation details remain unclear.The high wholesale cost of GLP-1 drugs could lead to increased premiums for Part D beneficiaries without substantial manufacturer rebates.Direct-to-consumer sales of obesity drugs offer lower prices but raise concerns about patient safety and […]
